Pharmacoeconomic evaluation of Ofatumumab in the management of relapsing-remitting multiple sclerosis patients: Narrative review
Main Article Content
Keywords
cost effectiveness analysis, cost utility , Ofatumumab, Disease-modifying therapies relapsing-remitting multiple sclerosis, Ofatumumab
Abstract
Ofatumumab offers new hope as the first medication of its kind for treating relapsing–remitting multiple sclerosis (RRMS); however, questions remain about its long-term effectiveness and affordability. This narrative review aims to provide concise and precise updates on the cost-effectiveness of ofatumumab in the management of RRMS. A literature search was conducted between 2020 and 2025 in English-language databases via the following keywords: RRMS, disease-modifying therapies (DMTs), ofatumumab, economic evaluation, cost-effectiveness, cost-utility, and cost consequences. The overall findings varied significantly by country, reflecting differences in methodological approaches, time horizons, analytical perspectives, and discount rates. The increase in quality-adjusted life years (QALYs) associated with the use of ofatumumab ranged from 0.17 (vs. ocrelizumab) to 1.26 (vs. BSC). The incremental cost- effectiveness ratio (ICER) ranged from $24,189 per QALY (vs. glatiramer acetate) to $28,014 per QALY (vs. BSC) in Canada. In the United Arab Emirates (UAE), ICERs ranged from Arab Emirates Dirham (AED) 108,221 ($29,463.64) per QALY (vs. interferon beta 1-alpha) to AED 256,238 ($69,761.92) per QALY (vs. BSC). However, the ICERs were higher than the WTP threshold compared to those of cladribine: AED was 713,068 ($194,135.90) per QALY in the UAE and $50,969 per QALY in Canada. Collective evidence from available studies indicates that ofatumumab is a cost-effective option compared with a range of DMTs, including ocrelizumab, dimethyl fumarate, fingolimod, intravenous natalizumab, teriflunomide, generic fingolimod, glatiramer acetate, interferon therapies, and BSC. To support informed decision-making further, future research should aim to generate robust data on the costs and health-related quality-of-life outcomes associated with ofatumumab and other DMTs.
References
2. Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology. 2006;66(11):1696-1702.
3. Bebo B, Cintina I, LaRocca N, Ritter L, Schmajuk G, Nguy A, et al. The Economic Burden of Multiple Sclerosis in the United States Estimate of Direct and Indirect Costs. Neurology. 2022;98(18):e1810-e1817.
4. Gallehzan NA, Khosravi M, Jamebozorgi K, Mir N, Jalilian H, Soleimanpour S, Hoseini S, Rezapour A, Eshraghi A. Cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing-remitting multiple sclerosis: a systematic review. Health Econ Rev. 2024;14(1):12.
5. Tullman MJ. Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis. Am J Manag Care. 2013;19(2 Suppl):S15-20.
6. Solaro C, Gamberini G, Masuccio FG. Depression in multiple sclerosis: epidemiology, etiology, diagnosis and treatment. CNS Drugs. 2018;32(2):117-133.
7. Etemadifar M, Nikanpour Y, Neshatfar A, Mansourian M, Fitzgerald S. Incidence and prevalence of multiple sclerosis in Persian gulf area: a systematic review and meta-analysis. Mult Scler Relat Disord. 2020;40:101959.
8. Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018;391(10130):1622-1636.
9. McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and Treatment of Multiple Sclerosis: A Review. JAMA. 2021;325(8):765-
779.
10. Albelo-Martínez M, Rizvi S. Progressive multiple sclerosis: Evaluating current therapies and exploring future treatment strategies. Neurotherapeutics. 2025. [Epub ahead of print].
11. Awada Z, Hameed N, Harel A. Profile of Ofatumumab in the Treatment of Multiple Sclerosis: Design, Development and Place in Therapy. Drug Des Devel Ther. 2024;18:5985-5996.
12. Baharnoori M, Bhan V, Clift F, Thomas K, Mouallif S, Adlard N, Cooney P, Blanchette F, Patel BP, Grima D. Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada. Pharmacoecon Open. 2022;6(6):859-870.
13. Samjoo IA, Worthington E, Drudge C, Zhao M, Cameron C, Haring DA, et al. Comparison of ofatumumab and other disease modifying therapies for relapsing multiple sclerosis: a network meta-analysis. J Comp Eff Res. 2020;9(18):1255-1274.
14. Schauf M, Chinthapatla H, Dimri S, Li E, Hartung D. Economic burden of multiple sclerosis in the United States: A systematic literature review. J Manag Care Spec Pharm. 2023;29(12):1354-1368.
15. Simoens S. Societal economic burden of multiple sclerosis and cost-effectiveness of disease-modifying therapies. Front Neurol. 2022;13:1015256.
16. Whetten-Goldstein K, Sloan FA, Goldstein LB, Kulas ED. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler. 1998;4(5):419-425.
17. Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology. 2006;66(11):1696-1702.
18. Hartung DM, Bourdette DN, Ahmed SM, Whitham RH. The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail? Neurology. 2015;84(21):2185-2192.
19. Earla JR, Thornton JD, Hutton GJ, Aparasu RR. Marginal health care expenditure burden among U.S. civilian noninstitutionalized individuals with multiple sclerosis: 2010-2015. J Manag Care Spec Pharm. 2020;26(6):741-749.
20. Racsa P, Kiss C, Stevens L, Dixon SW, Ellis JJ. A comparison of clinical, utilization, and cost outcomes between oral treatments for multiple sclerosis. J Manag Care Spec Pharm. 2024;30(2):129-140.
21. Paz-Zulueta M, Parás-Bravo P, Cantarero-Prieto D, Blázquez-Fernández C, Oterino-Durán A. A literature review of cost-of-illness studies on the economic burden of multiple sclerosis. Mult Scler Relat Disord. 2020;43:102162. Canadian Agency for Drugs and Technologies in Health (CADTH). Pharmacoeconomic Report: Ofatumumab (Kesimpta): (Novartis Pharmaceuticals Canada Inc.): Indication: Multiple Sclerosis, Relapsing-Remitting. 2021.
23. Barros BM, Correia MG, Tura BR, Magliano CS. Cost-Utility Analysis and Efficiency Frontier of Drugs Available in Brazil for the Treatment of Relapsing-Remitting Multiple Sclerosis. Value Health Reg Issues. 2025;48:101092.
24. Inshasi J, Nowier Y, Zimovetz EA, Moussa A, Shatila A, Hassan A, Farghaly M, Thakre M, Shakra M, Dallal SA, Noori SIA, Alabdin TZ, Khattab S, Yamout B. Cost-effectiveness of ofatumumab for the treatment of relapsing forms of multiple sclerosis in the United Arab Emirates. Ther Adv Neurol Disord. 2025;18:17562864251330260.
25. Smets I, Versteegh M, Huygens S, Corsten C, Wokke B, Smolders J. Health economic benefits of anti-CD20 treatments in relapsing multiple sclerosis estimated using a treatment-sequence model. Mult Scler J Exp Transl Clin. 2023;9(3):20552173231189400.
26. Bhan V, Clift F, Baharnoori M, Thomas K, Patel BP, Blanchette F, Adlard N, Vudumula U, Gudala K, Dutta N, Grima D, Mouallif S, Farhane F. Cost-consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada. J Comp Eff Res. 2023;12(9):e220175.
27. Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020;383(6):546-557.
28. Rezaee M, Ravangard R, Mojtabaeian SM, et al. Cost-effectiveness of oral versus injectable disease modifying therapies in relapsing multiple sclerosis: a systematic review analysis. BMC Health Serv Res. 2024;24:1288.
29. Siddiqui MK, Khurana IS, Budhia S, Hettle R, Harty G, Wong SL. Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing–remitting multiple sclerosis. Curr Med Res Opin. 2018;34(8):1361-1371.
30. Nabizadeh F, Mohamadi M, Rahmani S, Rajabi R, Afrashteh F, Najdaghi S, et al. Safety and efficacy of cladribine in multiple sclerosis: a systematic review and meta-analysis. Neurol Sci. 2023;44:1-13.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.